• Explore /
  • Poster
  • / Efficacy and safety of a combination of sintilimab, bevacizumab plus gemcitabine, and albumin-bound paclitaxel for initially unresectable gallbladder carcinoma: A prospective, single-arm phase II study.

Efficacy and safety of a combination of sintilimab, bevacizumab plus gemcitabine, and albumin-bound paclitaxel for initially unresectable gallbladder carcinoma: A prospective, single-arm phase II study.

Abstract Poster

Authors

null

Miao Wang

Liver Surgery Department, Shanghai Cancer Center, Shanghai, China

Miao Wang , Jiamin Zhou , Weiqi Xu , Qi Pan , Anrong Mao , Ning Zhang , Yun Feng , Xigan He , Zhenhai Lin , Longrong Wang , Yongfa Zhang , Hongxu Zhu , Zhiwe Ding , Yixiu Wang , Bingran Yu , Ti Zhang , Lu Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05757336

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 489)

DOI

10.1200/JCO.2024.42.3_suppl.489

Abstract #

489

Poster Bd #

C14

Abstract Disclosures

Similar Posters

First Author: Jianqing Zhu

First Author: Yongkang Xu

First Author: Jiwon Lee

First Author: Dong-Sheng Zhang